Immune-Mitochondrial Correction in Military Recruits

Summary

The goal of this clinical trial is to learn if a new immune-mitochondrial correction strategy works better than standard vitamins to prevent infections in young male military recruits during their first 6 months of service.

The main questions it aims to answer are:

1. Does the new strategy lower the number of recruits who get infections (like colds, flu, or pneumonia) over 6 months?
2. Does the new strategy improve how well the immune cells work, specifically their mitochondria (the power source inside cells)?

Researchers will compare:

* Control group (100 participants): Standard multivitamin taken once a day for 30 days
* Experimental group (100 participants): New strategy (sodium nucleinate, magnesium, vitamin B6, and vitamin D 5000 IU) taken as 3 tablets once a day for 30 days to see if the new strategy lowers infection rates more than standard vitamins.

Who can take part:

Healthy male military recruits aged 18-27 years who are starting their initial training at the Military Clinical Hospital in Almaty, Kazakhstan.

What participants will do:

Participants will be placed into one of the two groups by chance (like flipping a coin). They will:

* Take study pills once a day for 30 days
* Have blood draws 3 times over 6 months (baseline, 1 month, and 6 months)
* Have daily health checks by medical staff
* Complete quality of life questionnaires

What we will measure:

* Number of participants who get infections during 6 months
* How well the mitochondria in immune cells work (from blood samples)
* Immune system status
* Stress and adaptation levels
* Vitamin D and other blood markers

Risks and benefits:

The risks are very low. Participants may have mild discomfort or a small bruise from blood draws. All study pills are approved and registered in Kazakhstan.

There is no direct benefit to participants, but they will receive extra medical monitoring. The indirect benefit is helping develop a better prevention program to protect future recruits.

Where the study is taking place:

Military Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan, Almaty, Kazakhstan.

Study duration:

January 2027 to December 2028.

Conditions

• Respiratory Tract Infections (RTI)
• Meningitis
• Primary Prevention/Methods
• Primary Prevention
• Mitochondrial Biomarkers
• Immuno-monitoring
• Immuno-modulation

Interventions

DIETARY_SUPPLEMENT

Multivitamin/Mineral supplements

Standard multivitamin containing Vitamin A 800 mcg, Vitamin D3 200 IU (5 mcg), Vitamin E 10 mg, Vitamin C 60 mg, Vitamin B1 1.4 mg, Vitamin B2 1.6 mg, Vitamin B6 2 mg, Vitamin B12 1 mcg, nicotinamide 18 mg, pantothenic acid 6 mg, folic acid 200 mcg. One tablet orally once daily in the morning for 30 days.

DIETARY_SUPPLEMENT

Sodium nucleinate combination

Fixed-dose combination of sodium nucleinate 12 mg, magnesium citrate 400 mg, pyridoxine hydrochloride 6 mg, and vitamin D 5000 IU. Three tablets orally once daily in the morning for 30 days.

Sponsors & Collaborators

• MIPO Clinic

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

27 Years

Sex

MALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2027-01-01

Primary Completion

2027-12-31

Completion

2028-12-31